BL-M14D1: Clinical Trials

4 trials of BL-M14D1, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting. 2 Phase 1, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 12Recruiting 2
Phase 21Recruiting 1
Phase 31Recruiting 1

Follow BL-M14D1: new trials by email Literature Review of BL-M14D1 trials Research Report on BL-M14D1

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer
Phase 3RecruitingSystImmune Inc.5502026-08-042026-11-12
A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer
BL-M14D1, Atezolizumab - Extensive-stage Small-cell Lung Cancer
Phase 2RecruitingBiokin (Shanghai) Biopharmaceutical Co., Ltd.362026-07-092026-11-02
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
BL-M14D1 - Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer
Phase 1RecruitingSystImmune Inc.1202025-04-282026-11-12
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
BL-M14D1 - Small Cell Lung Cancer, Neuroendocrine Tumors
Phase 1RecruitingBiokin (Shanghai) Biopharmaceutical Co., Ltd.1152024-08-022026-11-02

Conditions studied

Small Cell Lung Carcinoma (3)  ·  Carcinoma, Neuroendocrine (1)  ·  Carcinoma, Small Cell (1)  ·  Lung Neoplasms (1)  ·  Neuroendocrine Tumors (1)

Sponsors

Biokin (Shanghai) Biopharmaceutical Co., Ltd. (2)  ·  SystImmune Inc. (2)

Countries

China (2)  ·  Georgia (2)  ·  United States (2)  ·  Australia (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Germany (1)  ·  Greece (1)  ·  Hungary (1)  ·  India (1)  ·  Italy (1)  ·  Poland (1)  ·  Serbia (1)

Top investigators

Caicun Zhou (1)  ·  Junliang Cai (1)  ·  Junliang Cai, MD (1)